Cathvision has announced “significant clinical and scientific progress” in pulsed field ablation (PFA) with its PFAnalyzer software module, which the company says reinforces its differentiated position in electrophysiology (EP) recording and analysis. The work demonstrates how high-fidelity unipolar electrograms can be re-established as a practical and clinically relevant tool in PFA workflows—addressing a “growing gap” between energy delivery and electrophysiologic feedback, according to Cathvision.
These findings have been published via a research letter in the journal Heart Rhythm. The study was conducted at the University Hospital of Split (Split, Croatia) in collaboration with Mount Sinai (New York, USA) and Cathvision.
The study confirms the existence of a clinically meaningful low-amplitude unipolar voltage threshold in the ~0.1mV range that can reliably distinguish between electrical silence and residual electrical activity following PFA, Cathvision reports in a press release. The company adds that these signals—typically filtered out or considered difficult to interpret—were measurable using its ECGenius EP recording system, and further processed and visualised in the PFAnalyzer module.
More specifically, the results demonstrate: clear separation between electrically silent tissue and residual local activity at voltage levels previously considered below the usable range; feasibility of using unipolar electrograms for objective lesion assessment in PFA; and actionable electrophysiologic feedback during procedures where operators today largely rely on surrogate endpoints.
Cathvision claims that, while PFA adoption has accelerated, direct electrophysiologic feedback has typically remained limited, increasing reliance on surrogate procedural endpoints—adding that, in this context, real-time unipolar electrogram analysis may provide clinically relevant insights into tissue effect at the time of ablation, supporting more informed procedural decision-making.
“What this work shows is that clinically meaningful information is still present in PFA—down to voltage levels we previously could not use,” said Ante Anić (University Hospital of Split, Split, Croatia). “With high-fidelity unipolar signals and tools like PFAnalyzer, signal analysis in electrophysiology becomes actionable again during the procedure, not just retrospectively.”
Cathvision also states in its recent press release that the company’s clinical progress in PFA will be highlighted via multiple presentations at the upcoming AF Symposium (5–7 February 2026, Boston, USA).
